Figure 2.

Reverse translation in microbiome studies using tailored microbial consortia.

(A) The process begins with the deep characterization of interventional and observational datasets, using proprietary computational algorithms and systems biology analytics to deconvolute microbial signatures and targets of disease. (B) This is followed by the design of tailored microbial consortia intended specifically to modulate functional targets based on hypothesized mechanisms. (C) Finally, therapeutic consortia are optimized using in vivo disease models, advanced strain libraries and data integration platforms.